AT-100

Phase 1Biologic

AAirway Therapeutics, Inc.

AT-100 is one of 72 biologic programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

PneumoniaActive, not recruiting

Bronchopulmonary DysplasiaPhase 1

Active, not recruiting

PneumoniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Preclinical

2 2

Jakafi

Incyte

Preclinical

1 3

Primaquine

Sanofi

Preclinical

1 4

Acanya

Pfizer

Preclinical

1 5

Prevacid

Takeda

Preclinical

1 6

Innohep

Alnylam Pharmaceuticals

Preclinical

1 7

Avlosulfon

AAlmirall, S.A.

Preclinical

4 8

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 9

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bronchopulmonary Dysplasia1 trial

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

Completed·AAirway Therapeutics, Inc.·Phase 1·NCT04662151·37 enrolled

Pneumonia1 trial

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

Terminated·AAirway Therapeutics, Inc.·Phase 1·NCT04659122·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AT-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AT-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AT-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Airway Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AAirway Therapeutics, Inc.

AT-100

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bronchopulmonary Dysplasia1 trial

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News